Electroconvulsive therapy

Silver Hill Hospital Launches Outpatient Ketamine Treatment Program for Depression

Retrieved on: 
Wednesday, February 14, 2024
Other Health, Research, Men, Managed Care, General Health, Consumer, Mental Health, Hospitals, Science, Women, Seniors, Health, Silver, Hospital, Silver Hill Hospital, Medical director, Ketamine, Electroconvulsive therapy, Patient, Nursing, DSM-IV codes, ECT, Mental, Environment, Depression

Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, has opened its Ketamine Treatment Program , bringing a powerful therapeutic intervention to patients with treatment-resistant depression.

Key Points: 
  • Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, has opened its Ketamine Treatment Program , bringing a powerful therapeutic intervention to patients with treatment-resistant depression.
  • With this opening, Silver Hill joins a select number of hospitals with comprehensive mental health services administering ketamine treatment.
  • In keeping with the environment of restorative care at Silver Hill, the Ketamine Treatment Program was deliberately designed to maximize comfort conducive to healing.
  • “With our research-backed protocol, expert medical staff, and the oversight of Dr. Prueitt, the Ketamine Treatment Program is poised to help patients who have not responded to more traditional depression treatment methods and may have been losing hope.”
    The Silver Hill Hospital Ketamine Treatment Program is available to outpatients, as well as inpatients and residential patients, and it is now accepting referrals.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon

Retrieved on: 
Monday, February 5, 2024
HOPE, Therapy, Patient, New Drug Application, FDA, Ketamine, Dark Enlightenment, NDA, ECT, Suicide, Electroconvulsive therapy, Insurance, DSM-IV codes, Pharmaceutical industry

This is designed with counsel to not be a taxable event for shareholders.

Key Points: 
  • This is designed with counsel to not be a taxable event for shareholders.
  • "Incorporating HOPE Therapeutics is another important step in building value for NRx shareholders.
  • HOPE is dedicated to providing an FDA-approved presentation of IV Ketamine, manufactured to current federal standards, in a diversion- and abuse-deterrent presentation.
  • NRx also expects to convene a shareholder meeting in the coming weeks to vote on the planned structure of the spin-out of Hope Therapeutics and the stock dividend.

Park Royal Hospital Offers Inpatient & Outpatient Electroconvulsive Therapy

Retrieved on: 
Tuesday, November 7, 2023
The American Journal of Psychiatry, Patient, Suicide, Education, The Lancet, Psychiatry, Electricity, Fear, Electroconvulsive therapy, Risk, Suicidal ideation, ECT, Brain, Depression, Safety, American Journal, Anesthesia, Death, Mental health, Pharmaceutical industry

FORT MYERS, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Park Royal Hospital, a premier provider of mental health and addiction treatment, is pleased to offer electroconvulsive therapy (ECT) for patients.

Key Points: 
  • FORT MYERS, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Park Royal Hospital, a premier provider of mental health and addiction treatment, is pleased to offer electroconvulsive therapy (ECT) for patients.
  • At Park Royal Hospital, ECT is available on an inpatient and outpatient basis and is delivered by a trained team of professionals.
  • Electroconvulsive therapy involves using a mild electrical current to stimulate the brain to produce a brief seizure while the patient is under general anesthesia.
  • Those who are interested in receiving ECT at Park Royal Hospital do not need a referral to inquire about treatment and can begin the admissions process anytime.

TrustPoint Hospital Offers Electroconvulsive Therapy in Inpatient & Outpatient Programs

Retrieved on: 
Tuesday, November 7, 2023
The American Journal of Psychiatry, Suicide, The Lancet, Psychiatry, Electroconvulsive therapy, Quality of life, Risk, Suicidal ideation, ECT, Depression, Safety, American Journal, Patient, Mental health, Pharmaceutical industry, Nursing

MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are struggling with severe symptoms of certain mental health disorders.

Key Points: 
  • MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are struggling with severe symptoms of certain mental health disorders.
  • TrustPoint Hospital offers inpatient and outpatient programs for patients who have a range of behavioral health concerns and need focused support.
  • ECT is available in all TrustPoint programs for adults age 18 and older.
  • “At TrustPoint Hospital, we’re committed to providing safe, efficient care that can positively transform patients’ quality of life,” said Brianna Motley, director of business development at TrustPoint.

Transcranial magnetic stimulation can treat depression. Developing research suggests it could also help autism, ADHD and OCD

Retrieved on: 
Monday, August 28, 2023
People, Technology, Maintenance, Depression, Tic disorder, OCD, Electroconvulsive therapy, ADHD, Psychotherapy, Brain, Research, Attention, COVID, Scalp, Disorder, Medicare, Addiction, Attention deficit hyperactivity disorder, Dementia, Patient, Smoke, Spectrum, Transcranial magnetic stimulation, Adolescence, Headache, Recurrence, Chronic pain, Hospital, Dietary supplement, Pharmaceutical industry, Nursing, Medical imaging, Vaccine

A new therapeutic option, especially for depression, transcranial magnetic stimulation, is slowly helping to address some of these considerable unmet needs in our community.

Key Points: 
  • A new therapeutic option, especially for depression, transcranial magnetic stimulation, is slowly helping to address some of these considerable unmet needs in our community.
  • Read more:
    Treating mental illness with electricity marries old ideas with modern tech and understanding of the brain – podcast

How does it work and who’s getting it now?

    • Transcranial magnetic stimulation involves the application of a series of magnetic pulses through a coil placed on the scalp.
    • They may include scalp discomfort, headache, tingling or facial twitching, and feeling lightheaded for a short time after a treatment session.
    • There is consistent evidence for the effectiveness of transcranial magnetic stimulation treatment for acute episodes of depression.
    • Studies both locally and overseas have started to show more efficient delivery and very rapid clinical benefits with these new treatment regimes.

What about for other conditions?

    • Alongside the clinical rollout of transcranial magnetic stimulation for depression, research is increasingly demonstrating its potential value in other conditions.
    • The treatment is showing promise for addiction disorders, including the development of an approach using transcranial magnetic stimulation to help patients stop smoking.
    • As clinical need escalates, early research is also exploring whether transcranial magnetic stimulation might alleviate symptoms of attention deficit hyperactivity disorder (ADHD).
    • Read more:
      People with obsessive-compulsive disorder have an imbalance of brain chemicals – our discovery could mean a treatment breakthrough

Do the effects last?

    • So far, the quality of the evidence on the persistence of effects and the need for maintenance treatment with the use of transcranial magnetic stimulation in depression is patchy.
    • Preliminary studies suggest maintenance treatment is effective, but there there have been insufficient high-quality studies to convince Medicare to provide a subsidy for it.
    • Medicare funding also does not fund the provision of transcranial magnetic stimulation for patients who experience the return of their depression on more than one occasion.

Fox Factory Holding Corp. Announces Definitive Agreement to Acquire Custom Wheel House, LLC, a Leading Designer, Marketer, and Distributor of High-Performance Wheels, Performance Off-Road Tires, and Accessories

Retrieved on: 
Tuesday, February 21, 2023
Hand, Electroconvulsive therapy, Fox Factory, LLP, Acquisition, SCA, Financial transaction, Family, MIT Blackjack Team, Nicolaus, Growth, FOX, CWH, Stifel, Video game, Retail

CWH, based out of Rancho Dominguez, California, designs, markets, and distributes high-performance wheels, performance off-road tires, and accessories.

Key Points: 
  • CWH, based out of Rancho Dominguez, California, designs, markets, and distributes high-performance wheels, performance off-road tires, and accessories.
  • “We are excited to announce the acquisition of Custom Wheel House, and believe it presents a substantial vertical integration and collaborative opportunity for FOX.
  • “When pushing the limits of ride dynamics, expanding the Company’s expertise from suspension to wheels and tires is a natural evolution.
  • Stifel, Nicolaus and Company served as the exclusive financial advisor to Custom Wheel House, LLC.

NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022

Retrieved on: 
Thursday, November 10, 2022
PTSD, ASIB, Neurological disorder, NMDA, Suicide, Depression, ET, Eastern Time Zone, Nasdaq, Webcast, Telephone, Risk, Private Securities Litigation Reform Act, Lurasidone, Breakthrough, Suicidal ideation, Earnings call, Brain, Electroconvulsive therapy, Goal, Ketamine, Company, FDA Special Protocol Assessment, Conference, Breakthrough therapy, SPA, Patient, Bipolar disorder, Therapy, Post-traumatic stress disorder, ECT, FDA, Internet service provider, Pharmaceutical industry

RADNOR, Pa., Nov. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022. The company will host a conference call and webcast on November 14, 2022, 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period.

Key Points: 
  • --Company to Host Conference Call November 14, 2022, at 8:00AM ET---
    RADNOR, Pa., Nov. 10, 2022 /PRNewswire/ --NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022.
  • NRx Pharmaceuticals to Host Conference Call & Webcast November 14, 2022, at 8:00 AM ET
    A live webcast of the conference call will be available on the Company's website at: NRx Pharmaceuticals Third Quarter 2022 Earnings Call.
  • NRx Pharmaceuticals expects to begin its registration trial for NRX-101 under a SPA in 4Q 2022 or early Q1/2023.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.

Homewood Health introduces its Interventional Psychiatry Service (IPS)

Retrieved on: 
Wednesday, October 19, 2022
Admission, The Residence, Holiday, Schizophrenia, IPS, Patient, Jagoda, Depression, Transcranial magnetic stimulation, Mental health, Bipolar disorder, ECT, Psychiatry, Esketamine, Trauma, Nasal administration, Physician, Electroconvulsive therapy, Brain, OHIP, Major depressive disorder, Pharmaceutical industry, Medical imaging, Ketamine

GUELPH, ON, Oct. 19, 2022 /CNW/ - Homewood Health announces the launch of its Interventional Psychiatry Service (IPS), featuring cutting-edge treatment options for individuals suffering from treatment-resistant depression and other mental health conditions.

Key Points: 
  • GUELPH, ON, Oct. 19, 2022 /CNW/ - Homewood Health announces the launch of its Interventional Psychiatry Service (IPS), featuring cutting-edge treatment options for individuals suffering from treatment-resistant depression and other mental health conditions.
  • Interventional Psychiatry is an emerging subspecialty within Psychiatry that encompasses various neuromodulation treatments such as Electroconvulsive Therapy (ECT) and Repetitive Transcranial Magnetic Stimulation (rTMS), as well as novel psychopharmacological agents such as ketamine.
  • Homewood's IPS delivers on its pledge to consistently provide innovative approaches to mental health and addiction treatment, combining evidence-based treatments, measurement-based care, and Homewood's deep expertise in mental health.
  • Homewood Health is a Canadian leader in the development and delivery of national, evidence-based mental health, trauma, and addiction treatment and services since 1883.

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference

Retrieved on: 
Thursday, September 8, 2022
Lists of diseases, Novartis, Treatment, BTD, Electroconvulsive therapy, Bipolar disorder, Brain, PTSD, Suicide, Goal, Ketamine, Lilly, Depression, SPA, Lurasidone, Conference, Nasdaq, Breakthrough therapy, FDA, ASIB, ECT, Risk, Private Securities Litigation Reform Act, Health, NMDA, Pharmaceutical industry, Pfizer, Patient, Company

RADNOR, Pa., Sept. 8, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting an update to the company's business at the H.C. Wainwright & Co. 24th Annual Global Investment Conference.

Key Points: 
  • The only FDA-approved treatment for patients with bipolar depression and acute suicidal ideation & behavior (ASIB) remains electroconvulsive therapy (ECT).
  • Conventional antidepressants can increase the risk of suicide in certain patients; hence their labels contain a warning to that effect.
  • NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.

PCORI approves $258 million to fund research studies addressing mental health, heart-related care, and a range of chronic and acute conditions

Retrieved on: 
Tuesday, July 26, 2022
Speech disorder, Congress, Plan, Gaps, Decision-making, Patient-Centered Outcomes Research Institute, English, Hospital, Research, Migraine, Health, Bipolar disorder, Adult, Opioid use disorder, COVID-19, Disability in Canada, Safety, Asthma, Appendicitis, Multimedia, Sinusitis, Cardiac rehabilitation, Appendectomy, Comparison, Suicidal ideation, Bone, Mental health, MHealth, Caregiver, Method, Patient, CER, Academic health science centre, Heart failure, Program, Electroconvulsive therapy, Communication, Population, Health insurance, Pharmaceutical industry, Medicine, PCORI

WASHINGTON, July 26, 2022 /PRNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) has approved funding awards totaling $258 million to support 26 new research studies. These studies aim to fill evidence gaps and improve health care decision making for a range of high-burden conditions among adults and children, including asthma, bone fractures, migraines, intellectual and developmental disabilities, and sinus infections.

Key Points: 
  • WASHINGTON, July 26, 2022 /PRNewswire/ --The Patient-Centered Outcomes Research Institute (PCORI) has approved funding awards totaling $258 million to support 26 new research studies.
  • Additionally, PCORI today announced about $3.9 million for two projects that aim to promote wider, faster adoption of useful findings from completed PCORI-funded CER studies into typical care practices.
  • The newly approved CER studies on mental health will expand an existing robust portfolio of PCORI-funded research examining the effectiveness of mental health care options for adults and children.
  • PCORI is committed to continuously seeking input from a broad range of stakeholders to guide its work.